Register Log-in Investor Type

Healthcare News

This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.

17 Jun 2019

Incyte reports positive outcome of topical rux in vitiligo

Incyte details positive outcome of topical rux in vitiligo Trust favourite Incyte (Nasdaq:INCY) saw its stock rise by 5% today after reporting positive results of a Phase II study of ruxolitinib cream  in the treatment of vitiligo (a condition characterised by de-pigmentation of skin) at a scientific conference over the weekend. Incyte, which is held by […]

17 Jun 2019

WPCT’s shares fall as FT questions value of BenevolentAI stake 

WPCT’s shares fall as FT questions value of BenevolentAI stake Woodford Patient Capital Trust’s share price fell by 5% today to 55p, after the Financial Times ran a story (see here) effectively questioning the £1.5bn carrying value ascribed to its largest holding – in BenevolentAI, a private, UK-based company purportedly using big data technology to […]

13 Jun 2019

Syncona to step up capital deployment after great year

Syncona to step up capital deployment after great year – Syncona has announced a whopping 37.9% return on NAV for the year ended 31 March 2019. It has transformed its portfolio so that life sciences investments now account for £1.06bn of the fund’s £1.46bn NAV. Some highlights: foundation of three highly innovative portfolio companies OMASS Therapeutics […]

06 Jun 2019

QuotedData’s other news 6 June 2019

In QuotedData’s other news 6 June 2019: Regional REIT has announced the sale of an office building in Sheffield at a price 25% higher than when it was last valued. Bought in 2016 for £6.3m, Aspect Court, Pond Hill, Sheffield was sold to Sheffield Hallam University for £8.8 million, reflecting a net initial yield of 6.6%. […]

05 Jun 2019

InflaRx stock crashes on study failure in HS

InflaRx stock crashes on study failure in HS US-listed German biotech InflaRx (Nasdaq: IFRX) saw its stock fall by 89% earlier today on the failure of a Phase IIb study of its lead product, IFX-1, in moderate to severe hidradenitis suppurativa (HS), a painful and chronic inflammatory skin disease. The study enrolled 179 patients who […]

04 Jun 2019

Verona Pharma starts Phase II of MDI-delivered ensifentrine in COPD

Verona Pharma starts Phase II of MDI-delivered ensifentrine in COPD Verona Pharma, the dual AIM (VRP) and Nasdaq (VRNA)-listed biotech specialising in respiratory disease, has started a Phase II dose-ranging trial of a metered-dose inhaler (MDI) formulation of its lead product ensifentrine in moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial is randomised, double-blind and […]

04 Jun 2019

Promising early clinical data on Sareum’s SRA737 presented at ASCO

Promising early clinical data on Sareum’s SRA737 presented at ASCO Sierra Oncology, the licence holder for the Sareum (SAR)-originated  SRA737, presented positive preliminary data from its two Phase I/II studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) conference over the weekend. The poster presentations cover preliminary clinical data from […]

29 May 2019

Genmab finally sets sights on Nasdaq

Genmab finally sets sights on Nasdaq Denmark’s Genmab, which has the distinction of being Europe’s largest biotech by market cap (DKK71.9bn/$10.7bn) and has filed with the US SEC to raise $500m through a US IPO of American depositary shares (ADS) on Nasdaq. The move is notable both for the proposed offering’s size as well as […]

29 May 2019

BioPharma Credit makes new loan to BioDelivery Sciences

BioPharma Credit makes new loan to BioDelivery Sciences – BioPharma Credit has entered into a  senior secured term loan agreement for up to US$80 million with BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a commercial-stage specialty pharmaceutical company with a current market capitalisation of approximately US$400 million. In addition, BioPharma Credit bought 5,000,000 BDSI shares at […]

28 May 2019

Biotech Growth extends run of poor performance

Biotech Growth extends run of poor performance – On Friday, Biotech Growth Trust published results for the year ended 31 March 2019. Its net asset value per share rose by 5.3% and the share price by 4.6%, reflecting a slight widening in the discount. The benchmark (Nasdaq Biotechnology Index) returned 13.0%. Biotech Growth Trust has now […]

22 May 2019

Amgen takeover of Nuevolution provides rare valuation for preclin immune/inflam assets

Amgen takeover of Nuevolution provides rare valuation for preclin immune/inflam assets US giant Amgen has announced an agreed takeover offer of SEK1.6bn (c$167m) for Nuevolution, a Swedish biotech, in a move which puts a monetary value of a small number of orally available preclincal assets, mostly in the immune/inflamamtory space. This area has seen relatively few […]

07 May 2019

Syncona’s Blue Earth gets good results in prostate cancer diagnosis

Syncona’s Blue Earth gets good results in prostate cancer diagnosis –  Syncona has a large stake in Blue Earth Diagnostics. Blue Earth has been testing its prostate cancer diagnosis at a university hospital in Germany. The test (a radiohybrid PSMA-targeted agent, rhPSMA-7) for high-risk primary and recurrent prostate cancer was bought by Blue Earth in […]

30 Apr 2019

Sareum to benefit from Lilly decision over competitor product

Sareum (SAR), together with its US-based licensee Sierra Oncology, should be a major beneficiary in competitive terms from an apparent decision by Lilly to discontinue development its Chk1 inhibitor, prexasertib. Sierra has the only other compound with this mechanism in clincial trials and, as a result, its Chk1 inihitibitor, SRA737 – which originated at Sareum […]

11 Apr 2019

Syncona establishes retinal gene therapy platform

Syncona establishes retinal gene therapy platform – Syncona has announced the merger of two of its companies, Gyroscope Therapeutics (Gyroscope), an ophthalmology company developing genetically defined therapies for retinal diseases and Orbit Biomedical (Orbit), a specialist medical device company focused on precision sub-retinal therapeutic delivery. Syncona will own 82% of the enlarged company (a holding value […]

03 Apr 2019

Sareum notes strong preclinical SCLC data on SRA737 at AACR

Sareum (SAR) has noted the presentation by its partner Sierra Oncology of preclinical data showing “profound synergy” for the triple combination of the CHK1 inhibitor SRA737 in combination with low-dose gemcitabine (LDG) and anti-PD-L1 immunotherapy in a mouse model of small cell lung cancer (SCLC). The data were reported in a late-breaking oral presentation at the […]

02 Apr 2019

Syncona/Woodford investment Autolus reports positive data

Syncona/Woodford investment Autolus reports positive data – Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London, has presented initial data from the ongoing Phase 1/2 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL). the presentation was made at the American Association of Cancer Research Annual Meeting 2019 in Atlanta, […]

26 Mar 2019

Dr Daniel Koller to step back from BB Healthcare

Bellevue fund manager Dr Daniel Koller to step back from BB Healthcare – Dr Daniel Koller, head of investments at Switzerland-based healthcare specialist, Bellevue, is to scale back his involvement with BB Healthcare Trust (BBH) and focus on the core Zurich-based BB Biotech AG (BION) company. Dr Koller’s Step back from BB Healthcare is a planned […]

21 Mar 2019

Biogen Alzheimer’s failure drags down Biotech Growth

Biogen Alzheimer’s failure drags down Biotech Growth – Biogen, a key holding in Biotech Growth Trust and a component of most other biotech and healthcare portfolios, has lost a third of its value after trials of an Alzheimer’s drug failed to show any benefit. Biogen and its partner, Japanese drugmaker Eisai, said they would stop […]

18 Mar 2019

Primary Health Properties to acquire new Kew medical centre for £4.6mn

Primary Health Properties to acquire new Kew medical centre for £4.6mn – Following its merger with MedicX Fund, Primary Health Properties (PHP) has announced that forward funding is in place for it to acquire a new primary healthcare medical centre in Kew, London. The property is due to be completed in October 2019 and will […]

15 Mar 2019

New shares in Primary Health tradeable following MedicX merger

New shares in Primary Health tradeable following MedicX merger – following on from the announcement on 14 March 2019 by MedicX Fund Limited and Primary Health Properties (PHP) that their merger had become unconditional in all respects, PHP announced that dealings in the new shares became effective at 8.00 a.m. today (March 15, 2019). The […]

14 Mar 2019

Wellcome Trust charity cuts stake in Syncona

Wellcome Trust charity cuts stake in Syncona – Wellcome Trust Limited, a UK biomedical charity, has confirmed that it has sold approximately 57 million ordinary shares in Syncona Limited (SYNC). This represents approximately 8.7% of Syncona’s issued ordinary share capital. The shares were sold at 245p per share, equating to gross proceeds of approximately £141m for […]

12 Mar 2019

Syncona shifting funds into cash

Syncona shifting funds into cash –  Syncona is changing the way it invests the portion of its portfolio that is not committed to biotech investments. It says: “Over the last two years, Syncona has evolved the investment parameters of its strategic capital pool to focus on liquidity and capital preservation in order to support Syncona’s […]

12 Mar 2019

Primary Health Properties to acquire The Meath Primary Healthcare Centre in Dublin 8

Primary Health Properties (PHP) has announced that it has contracted to acquire a The Meath Primary Healthcare Centre, in Dublin 8, for a total cost of €10.9 million. The transaction is being conducted through Primary Health Properties ICAV, an Irish investment vehicle that is wholly owned by PHP. This acquisition, which has a completion date […]

07 Mar 2019

Caledonia Investments acquires minority stake in BioAgilytix

Caledonia Investments acquires minority stake in BioAgilytix – Caledonia has invested a minority stake in US-based pharmaceutical services business BioAgilytix, which specialises in bioanalytical testing solutions for molecule research and development. Caledonia has invested alongside Cobepa (a Belgium and US-based investment company), which it has a 5% shareholding in. BioAgilytix has offices in Raleigh, North […]

06 Mar 2019

Symphony International suffering, NAV and share price decline sharply

Symphony International suffering, NAV and share price decline sharply – Symphony International Holdings has realised a substantial loss on both share price and NAV in their 2018 results. NAV declined 24% in 2018, moving from $1.27 per share to $0.96 per share, a roughly 24% decrease. This comes as a result of one of the […]

04 Mar 2019

Syncona’s Nightstar Therapeutics to be sold for $877m

Syncona’s Nightstar Therapeutics to be acquired for $877m – Syncona Limited founded Nightstar Therapeutics in 2013, with an original investment of £56.4m. Syncona’s holding of Nightstar at the time of sale was £254.6m, a £135.4m uplift previous valuation. This results in a 4.5x multiple on Syncona’s original investment and an internal rate of return (IRR) […]

26 Feb 2019

Syncona funds new immuno-oncology company

Syncona funds new immuno-oncology company – Syncona is contributing CHF 28 million (GBP21.4 million) to a CHF 35 million (GBP26.8 million) fundraising being carried out by Anaveon, a new immuno-oncology company. Syncona will have a 47.0 per cent stake in the business. Anaveon was founded in December 2017 by leading experts in the field of immunotherapy, […]

15 Feb 2019

BB Healthcare has “another successful year”

BB Healthcare Trust has announced its annual results for the year ended 30 November 2018. During what the trust’s chairman, Professor Justin Stebbing, describes as “another successful year”, the trust provided Nav and share price total returns of 24.0% and 21.6% respectively. These returns are ahead of the MSCI World Healthcare Index, which it says […]

24 Jan 2019

Primary Health and MedicX to merge

Primary Health and MedicX to merge – The boards of Primary Healthcare Properties (PHP) and MedicX Fund have reached agreement on the terms of a recommended all-share merger between MedicX and PHP, which is intended to be structured as  PHP acquiring the entire issued and to be issued share capital of MedicX. Under the terms of […]

23 Jan 2019

WWH opens new positions in Takeda and Novartis  

WWH opens new positions in Takeda and Novartis Orbimed-managed Worldwide Healthcare Trust (WWH) has disclosed new substantial shareholdings in Takeda – the Japanese pharmaceuticals group that has just completed a takeover of Shire Pharmaceuticals – and Novartis, according to an analysis by Marten & Co. The shareholding in Takeda appears in third place and accounts for […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…